Company Overview and News

 
ITL Health's Biomedical division launches laboratory blood culture testing product

2018-03-27 proactiveinvestors.com.au
ITL Health Group (ASX:ITD), has launched a new product from its ITL BioMedicals division which supports the microbiology laboratory blood culture testing process.
Upvote Downvote

 
ITL extends contract with large U.S. community blood bank

2017-07-25 proactiveinvestors.com.au
ITL’s (ASX:ITD) ITL BioMedical division has won a 12-month contract extension with a large U.S. community blood bank for its SampLok Sampling Kit.
Upvote Downvote

 
ITL Health Group secures $2.6M grant to develop new testing methods

2017-06-28 proactiveinvestors.com.au
ITL Health Group’s (ASX:ITD) subsidiary MyHealthTest has been awarded a $2.6 million CRC-Project grant for the development of new health testing methods using dried blood spot samples.
Upvote Downvote

 
ITL Health Group expects strong growth in financial results

2017-06-14 proactiveinvestors.com.au
ITL Health Group (ASX:ITD) is expecting a positive FY2017 result with the current half showing significant improvements over the corresponding period last year.
Upvote Downvote

 
ITL Health Group wins supply contract with New Zealand Blood Service

2017-04-19 proactiveinvestors.com.au
ITL Health Group’s (ASX:ITD) ITL BioMedical division has signed a two year supply agreement for its SampLok Sampling Kit (SSK) with New Zealand Blood Service (NZBS).
Upvote Downvote

 
ITL Limited pasa a llamarse ITL Health Group con el fin de unificar sus divisiones bajo una marca mundial única

2017-03-01 prnewswire
MELBOURNE, Australia, 1 de marzo de 2017 /PRNewswire/ -- ITL Limited (ASX:ITD), una innovadora compañía mundial de tecnología médica, proveedor y socio estratégico que proporciona productos y soluciones innovadores para los mercados del cuidado de la salud y que otorga poder al cuidado de la salud individual, anuncia formalmente su cambio de nombre por el de ITL Health Group (ITL).
Upvote Downvote

 
ITL Limited Rebrands to ITL Health Group to Unify Divisions under a Global Brand

2017-02-28 prnewswire
MELBOURNE, Australia, Feb. 28, 2017 /PRNewswire/ -- ITL Limited (ASX:ITD), an innovative global medical technology company, supplier and strategic partner that provides innovative products and solutions to healthcare markets and empowers individual health management, formally announces its rebrand to ITL Health Group (ITL).
Upvote Downvote

 
El beneficio de ITL se duplica para los resultados de mitad de año 2016/2017

2017-02-24 prnewswire
MELBOURNE, Australia, 24 de febrero de 2017 /PRNewswire/ -- ITL Limited, (ASX: ITD), una compañía sanitaria diversificada, se complace anunciar resultados excelentes para la primera mitad del año finalizado el 31 de diciembre de 2016 en comparación con el periodo anterior correspondiente. Una presentación completa de "Results and ITL BioMedical Growth Update" puede visualizarse aquí.
Upvote Downvote

 
ITL BioMedical Announces Distribution Agreement with bioMérieux Canada

2016-12-13 prnewswire
MELBOURNE, Australia, Dec. 13, 2016 /PRNewswire/ -- ITL BioMedical, a division of ITL (ASX: ITD), that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce it has signed a five year distribution agreement, with possible ongoing renewals, for its Safety SubCulture Unit (SCU) with bioMérieux Canada, Inc.  The total estimated number of subculture procedures performed in the Canadian market per year is between 700,000 to one million.
Upvote Downvote

 
ITL BioMedical Announces Early Sales of Recently Launched New Product DonorCare Needle Guard 2

2016-11-16 devicespace
MELBOURNE, Australia, Nov. 16, 2016 /PRNewswire/ -- ITL BioMedical, a division of ITL (ASX: ITD) that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce that after launching its highly innovative patented DonorCare Needle Guard 2 mid-October the Company has already achieved significant sales in excess of one million products.
Upvote Downvote

 
ITL BioMedical Announces Early Sales of Recently Launched New Product DonorCare® Needle Guard 2

2016-11-16 prnewswire
MELBOURNE, Australia, Nov. 16, 2016 /PRNewswire/ -- ITL BioMedical, a division of ITL (ASX: ITD) that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce that after launching its highly innovative patented DonorCare Needle Guard 2 mid-October the Company has already achieved significant sales in excess of one million products.
Upvote Downvote

 
ITL BioMedical Announces Global Launch Of DonorCare Needle Guard 2

2016-11-09 devicespace
MELBOURNE, Australia, Nov. 8, 2016 /PRNewswire/ -- ITL BioMedical, a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce the global launch of its highly innovative patented DonorCare Needle Guard 2 that took place at the American Association of Blood Banks (AABB) Annual Meeting in Orlando, Florida, the premier event for healthcare professionals in transfusion medicine and cellular therapies.
Upvote Downvote

 
ITL BioMedical Announces Global Launch of DonorCare® Needle Guard 2

2016-11-08 prnewswire
MELBOURNE, Australia, Nov. 8, 2016 /PRNewswire/ -- ITL BioMedical, a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce the global launch of its highly innovative patented DonorCare Needle Guard 2 that took place at the American Association of Blood Banks (AABB) Annual Meeting in Orlando, Florida, the premier event for healthcare professionals in transfusion medicine and cellular therapies.
Upvote Downvote

 
ITL Ltd to wins contract to supply Macquarie University Hospital

2016-09-30 proactiveinvestors.com.au
ITL Ltd (ASX:ITD) has signed a five year contract with Macquarie University Hospital in Sydney to supply ITL’s invasive blood pressure monitoring systems. The contract is estimated to be worth $0.5 million and includes two new innovative product solutions from ITL Healthcare: - Needle-free closed Arterial Blood Sampling System, which helps to prevent injuries, infections and minimise blood loss when taking blood samples during invasive blood pressure monitoring.
Upvote Downvote

 
ITL Ltd ranked 16th among Australia’s most innovative companies

2016-08-23 proactiveinvestors.com.au
ITL Ltd (ASX:ITD) has been ranked the 16th most innovative company in Australia on The Australian Financial Review’s (AFR) 50 Most Innovative Companies of 2016 list. The AFR Most Innovative Companies list ranks the most innovative organisations in Australia, and is the only national, cross-industry list of its kind. ITL is focused on its fully owned subsidiary MyHealthTest, which sells direct-to-consumer pathology testing for major chronic diseases.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...